Evaluation of Circulating Tumor DNA as a Biomarker for Chemoresistance in Colorectal Cancer
Elevated baseline ctDNA levels and persistent TP53 mutations are associated with chemoresistance in colorectal cancer. Early reduction in ctDNA during therapy may serve as a robust predictor of response, supporting its integration into personalized treatment strategies.
Authors
- Parvin F. Peddi (ORCID: https://orcid.org/0000-0002-8459-9828)
- Chandrasekaran Sankaranarayanan (ORCID: https://orcid.org/0000-0002-5129-2301)
- K Vijaya Lakshmi (ORCID: https://orcid.org/0000-0002-9961-8884)
- Karim Shaheen
- Raja A. S. Gogineni
Institutions
- PSG Institute of Medical Sciences & Research (IN)
- CARE Hospitals (IN)
- Mamata Medical College (IN)
- Yashoda Hospital (IN)
- Manipal Hospital (IN)
Publication Details
- Journal
- Journal of Pharmacy And Bioallied Sciences
- Published
- 2025-12-01
- DOI
- https://doi.org/10.4103/jpbs.jpbs_1319_25
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00